Emerging Therapeutic Strategies in Metastatic Hormone-Sensitive Prostate Cancer.

Area of Science:

• Oncology
• Urology

Background:

• Prostate cancer is a leading malignancy in the US, with rising metastatic incidence.
• Androgen deprivation therapy (ADT) is standard for metastatic prostate cancer, but castration resistance eventually develops.

Purpose of the Study:

• To review current and emerging treatments for metastatic hormone-sensitive prostate cancer (mHSPC).
• To guide clinical decision-making by synthesizing evidence on novel therapeutic modalities.

Main Methods:

• Comprehensive review of existing literature on mHSPC treatments.
• Analysis of current evidence for cytotoxic chemotherapy, androgen receptor pathway inhibitors (ARPIs), radiotherapy, radiopharmaceutical therapy, immunotherapy, and PARP inhibitors.
• Discussion of emerging biomarkers for prognostication and therapeutic guidance.

Main Results:

• Novel treatment modalities are expanding the armamentarium for mHSPC.
• The treatment landscape is shifting towards precision oncology with combined systemic therapies.
• Emerging biomarkers aid in guiding treatment decisions and improving prognostication.

Conclusions:

• The management of mHSPC is rapidly advancing with new therapeutic options.
• Precision medicine approaches, incorporating biomarkers and combined therapies, are becoming central to mHSPC treatment.
• Continued research and clinical trials are essential to optimize mHSPC care.